Clinical trialPhase 2Terminated
Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer
Autologous Cytokine-induced Killer Cells Combined Chemotherapy in Advanced Pancreatic Cancer: A Prospective, Randomized, Open, Single Center Phase II Study
- Outcome
- Stopped earlyStudy halted prematurely and will not resume (Other)
- Phase
- Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- November 2016
- Expected end
- October 2019
- Enrollment
- 13 participants
- Sites
- 1
- Primary outcomes
- Overall Survival
- Sponsor
- Other gov
- Results posted
- No
- Last update
- 2 April 2020
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- Registry-listed results paperAutologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. DOI 10.1186/s13045-016-0237-6↗
- Registry-listed results paperClinical outcome of elderly patients with unresectable pancreatic cancer treated with gemcitabine plus S-1, S-1 alone, … DOI 10.1016/j.ejca.2015.11.002↗
The registry lists these as results papers; in a hand check of 27 such links about 78% reported the trial’s results, so read the paper before treating it as the outcome.